4th African Regulatory Conference

Moving towards Regulatory Harmonisation to enhance Access to Medicines in Africa

27-28 April 2015
King Fahd Palace Hotel, Dakar, Senegal

PROGRAMME CO-CHAIRS:
Dr Vincent I. Ahonkhai
Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Dr Corneille Traore
Director, West African Economic and Monetary Union (UEMOA), Burkina Faso

PROGRAMME COMMITTEE:
Ms Mercè Caturia, Janssen Pharmaceutical companies of Johnson & Johnson, Belgium, IFPMA ARN Chairperson
Ms Fabienne Benoist, Novartis Pharma AG, Switzerland, IFPMA ARN Deputy Chairperson
Ms Nouara Ait-Aider, Sanofi, Switzerland
Ms Cristina Arnes, IFPMA, Switzerland
Ms Caroline Mendy, Pfizer, Nigeria
Mr Robert Lebeda, Eli Lilly, Austria
Ms Carolinie Mndy, IFPMA, Switzerland
Ms John Mwangi, Bayer Healthcare, Kenya
Ms Sharmilla Parsotam, Pfizer Ltd, UK
Mr Dakshina Reddy, Novartis Pharma AG, South Africa
Mr Christophe Saillez, GlaxoSmithKline, Belgium
Ms Myriam Sediati, Merck Sharp & Dohme, Morocco
Ms Nathalie Tatarczuk, MSD, Morocco

WHO WILL ATTEND
Representatives of health authorities, regulatory affairs, quality assurance, medical, safety, research and development professionals, and other professionals involved in or interested in the aspects surrounding registration of medicinal products and regulatory harmonisation initiatives in Africa.

OVERVIEW
This is the 4th African-Regulatory Conference co-organised by the DIA and the IFPMA’s African Regulatory Network (ARN).

IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 1.3 million employees strive to develop and provide innovative medicines, biological products, and vaccines that improve patients’ lives worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

The ARN is an ad-hoc network of the Regulatory Policy and Technical Standards Committee (RPTS) of IFPMA. The association works in partnership with regulatory authorities and the pharmaceutical industry in Africa to encourage greater harmonisation of regulatory requirements with the aim to help enable faster and expanded access to good quality innovative medicines for patients.

The African Regulatory Conference offers the opportunity for key stakeholders active in the region including Representatives from health authorities, local and multinational pharmaceutical companies, international, governmental and non-governmental organisations to exchange progressive views on key topics of interest and identify focus areas for ongoing efforts aimed to increase patient access to new and improved medicines.

OBJECTIVES
Following the successful discussions held during the 3rd African Regulatory Conference in 2012 in Ghana, this edition intends to build on progress made within the region and to identify further initiatives for stakeholders to work together on the enhancement of healthcare in Africa.

This 4th African Regulatory Conference will provide an overview of regulatory harmonisation initiatives currently ongoing or emerging in Africa and will offer the opportunity to:
• Provide a platform to foster collaboration between African regulatory authorities and the pharmaceutical industry
• Share information and best practices
• Openly discuss issues faced by African regulatory authorities and industry
• Identify and agree on key proposals stemming from conference discussions for further assessment and action
• Strongly oriented towards informing on the current evolving regulatory landscape in Africa, and leveraging pragmatic and efficient approaches that strengthen ongoing harmonisation/convergence efforts, the conference will include panel discussions delivered during plenary and breakout sessions to maximise contributions from participants and enable deep-dived discussions of the key topics.

KEY TOPICS
• African Medicines Regulatory Harmonisation (AMRH)
• Guidelines development and implementation
• Common technical documentation
• Submission requirements
• Transparency / Good Regulatory Practices
• Clinical trials capacity building
• Dossier assessment
• End-to-end submission and approval process mapping
• Variations management
• Quality / Good Manufacturing Practices (GMP) / Inspections
• Transparency / Good Regulatory Practices

Simultaneous translation in French and English will be available.

FINAL PROGRAMME
DAY 1 – MONDAY | 27 APRIL 2015
CURRENT REGULATORY LANDSCAPE AND INITIATIVES (LESSONS LEARNT)

07:30 | REGISTRATION AND WELCOME COFFEE
CONFERENCE CENTRE FOYER AND ROOM B01

08:30 | SESSION 1 – OPENING | ROOM BC12

DIA Opening Remarks
Jytte Lyngvig, Senior Vice President and Managing Director DIA Europe, Middle East & Africa, Switzerland

Keynote Address
Representative invited, Ministry of Health and Prevention, Senegal

IFPMA / ARN Introduction
Mercè Caturla, IFPMA ARN Chairperson, Belgium

Welcome Note by Partners and Sponsors
Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Andreas Seiter, Senior Health Specialist – Pharmaceuticals, World Bank, USA

09:15 | SESSION 2 – PLENARY | ROOM BC12

CURRENT REGULATORY LANDSCAPE IN AFRICA – LATEST DEVELOPMENTS
This session will provide participants with the evolution in the Regulatory Landscape in Africa since 2008 when the first ARC was organized in South Africa and an overview of other initiatives on going in the region to further advance regulatory science.

Chairs: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA, and Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso

2008-2015 ARC Roadmap
Osaretin Jaiyeola, Managing Director & Principal Consultant, Fensyl MHP Consulting Limited, Ghana
Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso

09:45 | SESSION 3 PART 1 – PLENARY | ROOM BC12

LEVERAGING ACTIVITIES BETWEEN REGULATORY AGENCIES / BODIES
This session will provide participants with an opportunity to get an update from regulatory agencies on the African Medicines Regulatory Harmonization (AMRH) programme. Key implementation learning amongst agencies and within the industry shall be shared in the 1st part of the session.

Chair: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Samvel Azatyan, Group Lead, Capacity Building and Harmonization Support, World Health Organization (WHO), Switzerland
Mauricio Cantú González, Federal Commission for the Protection against Sanitary Risk (COFEPRIS), Mexico
Petra Doerr, Head of Communication and Networking, Deputy Director, Swissmedic, Switzerland
William Mwatu, Chairman, Kenya Association of the Pharmaceutical Industry (KAPI), Kenya

10:30 | COFFEE BREAK & NETWORKING IN THE EXHIBITION HALL
ROOM B01

11:00 | SESSION 3 PART 2 – PLENARY | ROOM BC12

LEVERAGING ACTIVITIES BETWEEN REGULATORY AGENCIES / BODIES
This session will provide participants with an opportunity to get an update from regulatory agencies on the African Medicines Regulatory Harmonization (AMRH) programme. Key implementation learning amongst agencies and within the industry shall be shared in the 1st part of the session.

Chair: Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
John Patrick Mwesigye, Senior Health Officer (MRH), East African Community (EAC) Secretariat, Tanzania
Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Sybil Nana Ama Ossei-Agyeman-Yeboah, Professional Officer in Charge, Essential Medicines and Vaccines, West African Health Organization (WAHO), Burkina Faso
Emilienne Yissibi Pola, Public Health Pharmacist, Organization for the coordination of the fight against endemic diseases in central Africa (OCEAC), Cameroon
Luther Gwaza, Lead Consultant ZaZiBoNa initiative, Medicines Control Authority of Zimbabwe, Zimbabwe
Jacinta Wasike, Director, Inspection Surveillance and Enforcement, Pharmacy and Poisons Board, Kenya
Estelle Taute, Director: Operations and Administration, Medicines Regulatory Authority, South Africa

12:30 | LUNCH
SALON FLAMBOYANT
### Workshop A | Room BC12

**How to Reach One Dossier for All: Good review practice and regulatory convergence in Africa**

This session will be a panel discussion between regulatory agencies and the representatives of the industry. It is an opportunity to share and exchange the experiences of each counterpart (dossier preparation for the industries and dossier evaluation for the authorities).

- **Chair:** Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
- **Moderator:** Elliot P. Simonian, Director, Emerging Markets, Global Regulatory Affairs, GlaxoSmithKline, United Kingdom
- **Rapporteur:** Paul Dearden, Director, Regulatory Policy & Intelligence, AbbVie, United Kingdom
- **Speakers:**
  - Amadou Moctar Dieye, Director, Direction de la Pharmacie et du Medicament, Senegal
  - Hiiti Baran Sillo, Director General, Tanzania Food and Drugs Authority (TFDA), Tanzania
  - Elliot P. Simonian, Director, Emerging Markets, Global Regulatory Affairs, GlaxoSmithKline, United Kingdom

### Workshop B | Room C01

**Improving GMP Compliance in Africa; The need to create an opportunity for pragmatic dialogue between MRA and industry**

How can we move towards a proactive, mutual process improvement of the current change control process across the African region such that supply continues without disruption and patients do not suffer when shortages are avoidable?

- **Moderator:** Carl Engleman, Country Manager, Nigeria & East Africa Region, Pfizer, United Arab Emirates
- **Rapporteur:** Jacinta Wasike, Director, Inspection Surveillance and Enforcement, Pharmacy and Poisons Board, Kenya

### Workshop C | Room B05+06

**Clinical Trials in Africa – Challenges and opportunities in building capacity**

Participants will hear from regulators and industry about the status of clinical trials in Africa. The capacity building situation and its impact in multi-regional clinical trials, the role of the regulators in reviewing the trial protocol to ensure safety for its population, the appropriateness of its scientific design, and that the protocol will be executed ethically will also be discussed.

- **Chair:** Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
- **Moderator:** Kirti Narsai, Director, Government Affairs and Policy, Johnson & Johnson Medical, South Africa
- **Rapporteur:** Delese Mimi Darko, Ag. DCE; Safety Monitoring & Clinical Trials Division, Food and Drugs Authority, Ghana

---

**15:30 | COFFEE BREAK & NETWORKING IN THE EXHIBITION HALL**

**16:00 | SESSION 4 CONTINUED – CHOOSE FROM 3 PARALLEL WORKSHOPS**

**16:30 | SESSION 5 – PLENARY | ROOM BC12**

**RECAP FROM PARALLEL WORKSHOPS, DISCUSSIONS AND WRAP-UP**

- **Chair:** Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
- **Moderators:**
  - Paul Dearden, Director, Regulatory Policy & Intelligence, AbbVie, United Kingdom
  - Jacinta Wasike, Director, Inspection Surveillance and Enforcement, Pharmacy and Poisons Board, Kenya
  - Delese Mimi Darko, Ag. DCE; Safety Monitoring & Clinical Trials Division, Food and Drugs Authority, Ghana
- **Speakers:**
  - Elliot P. Simonian, Director, Emerging Markets, Global Regulatory Affairs, GlaxoSmithKline, United Kingdom
  - Carl Engleman, Country Manager, Nigeria & East Africa Region, Pfizer, United Arab Emirates
  - Kirti Narsai, Director, Government Affairs and Policy, Johnson & Johnson Medical, South Africa

**17:30 | CONFERENCE NETWORKING RECEPTION IN THE EXHIBITION HALL**

**19:00 | END OF DAY ONE**
DAY 2 – TUESDAY | 28 APRIL 2015
IMPLEMENTATION AND PRAGMATIC APPROACHES (PROCESS OPTIMISATION)
08:30 | SESSION 6 – OPENING | ROOM BC12

REFLECTIONS AND OVERVIEW OF DAY ONE AND INTRODUCTION TO DAY TWO
Chairs: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA, and Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Osaretin Jaiyeola, Managing Director & Principal Consultant, Fensyl MHP Consulting Limited, Ghana
Fabienne Benoist, Tropical Medicines Global brand regulatory director, Novartis Pharma AG, Switzerland

09:00 | SESSION 7 – PLENARY | ROOM BC12

OPTIMISED DOSSIER REVIEW PROCESS
Dossier review processes in different African countries are evolving over time and new registration requirements are being implemented. Variety and differences in requirements have led to increased review timelines and prolonged access for patients to medicines. This session targets to evaluate possibilities to optimise dossier review processes in different African regions and countries. Input will be brought in from the European Union where collaboration between countries has evolved and led to a harmonised approach and work-sharing between countries. The current situation in Africa will be analysed and recommendations be given how to improve processes, and show possibilities for harmonisation and collaboration between African countries.

Chairs: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA, and Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Moderator: Milan Smid, Department of Essential Medicines and Health Products (EMP), World Health Organization (WHO), Switzerland
Amadou Moctar Dieye, Director, Direction de la Pharmacie et du Medicament, Senegal
Margareth Ndomondo-Sigonda, New Partnership for Africa’s Development (NEPAD), South Africa
Hiti Baran Sillo, Director General, Tanzania Food and Drugs Authority (TFDA), Tanzania

10:30 | COFFEE BREAK & NETWORKING IN THE EXHIBITION HALL | ROOM B01

11:00 | SESSION 8 – CHOOSE FROM 3 PARALLEL WORKSHOPS

**Workshop D | Room C01**
Innovative Pathways for Expedited Regulatory Approvals
This session will give an overview of new / expedite regulatory pathways for medicines and vaccines, as well as analyse lessons learnt from existing innovative/pilot pathways: what could be replicated and what should be avoided. Opportunities and recommendations will be discussed.
Chair and Moderator: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Rapporteur: Rasmane Semde, General Director, Direction de la Pharmacie et du Medicament, Burkina Faso
Samvel Azatyan, Group Lead, Capacity Building and Harmonization Support, World Health Organization (WHO), Switzerland
Milan Smid, Department of Essential Medicines and Health Products (EMP), World Health Organization (WHO), Switzerland
Luther Gwaza, Lead Consultant ZaZiBoNa initiative, Medicines Control Authority of Zimbabwe, Zimbabwe
Fabienne Benoist, Tropical Medicines Global brand regulatory director, Novartis Pharma AG, Switzerland

**Workshop E | Room B05+06**
The Complex Journey of a Vaccine – Questions on access from a regulatory angle
This session will cover the availability of vaccines in Africa and the complex journey a vaccine has to make, from being manufactured to their assessment by regulatory bodies, and their availability to patients. The session will also include a discussion that will focus on how effective and efficient review processes and capacity building through convergence, cooperation and partnerships can improve access to vaccines and support the future needs of Africa.
Chair and Moderator: Ahmed Bellah, World Health Organization (WHO), Switzerland
Rapporteur: Yakubu Nyam Beno, Chair, African Vaccine Regulatory Forum (AVAREF), Nigeria
Christophe Saillez, Senior Manager GSK Biologicals, Belgium

**Workshop F | Room BC12**
Capacity Building – Training of medicines development and regulatory sciences in emerging countries
This session will cover the need for developing and improving the medicine regulatory capacity in emerging countries with a focus on Africa as a mean to improve regulatory review and approval timelines and drive earlier access to medicines. There are currently numerous projects underway in Africa and this session will further explore the efforts towards optimising our resources.
Chair: Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Moderator: Alexander Dodoo, Director, The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Ghana
Rapporteur: Sandor Kerpel-Fronius, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Hungary
Margareth Ndomondo-Sigonda, New Partnership for Africa’s Development (NEPAD), South Africa
Oluwaseun Ayobami Omobo, Technical Assistant, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria

**Workshop G | Room BCD12**
Capacity Building – Training of medicines development and regulatory sciences in emerging countries
This session will cover the need for developing and improving the medicine regulatory capacity in emerging countries with a focus on Africa as a mean to improve regulatory review and approval timelines and drive earlier access to medicines. There are currently numerous projects underway in Africa and this session will further explore the efforts towards optimising our resources.
Chair: Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Moderator: Alexander Dodoo, Director, The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Ghana
Rapporteur: Sandor Kerpel-Fronius, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Hungary
Margareth Ndomondo-Sigonda, New Partnership for Africa’s Development (NEPAD), South Africa
Oluwaseun Ayobami Omobo, Technical Assistant, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria

**Workshop H | Room B04**
Capacity Building – Training of medicines development and regulatory sciences in emerging countries
This session will cover the need for developing and improving the medicine regulatory capacity in emerging countries with a focus on Africa as a mean to improve regulatory review and approval timelines and drive earlier access to medicines. There are currently numerous projects underway in Africa and this session will further explore the efforts towards optimising our resources.
Chair: Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Moderator: Alexander Dodoo, Director, The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Ghana
Rapporteur: Sandor Kerpel-Fronius, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Hungary
Margareth Ndomondo-Sigonda, New Partnership for Africa’s Development (NEPAD), South Africa
Oluwaseun Ayobami Omobo, Technical Assistant, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria

**Workshop I | Room BCD12**
Capacity Building – Training of medicines development and regulatory sciences in emerging countries
This session will cover the need for developing and improving the medicine regulatory capacity in emerging countries with a focus on Africa as a mean to improve regulatory review and approval timelines and drive earlier access to medicines. There are currently numerous projects underway in Africa and this session will further explore the efforts towards optimising our resources.
Chair: Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Moderator: Alexander Dodoo, Director, The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Ghana
Rapporteur: Sandor Kerpel-Fronius, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Hungary
Margareth Ndomondo-Sigonda, New Partnership for Africa’s Development (NEPAD), South Africa
Oluwaseun Ayobami Omobo, Technical Assistant, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria
12:00  SESSION 9 – PLENARY | ROOM BC12

RECAP FROM PARALLEL WORKSHOPS, WRAP-UP

Chair: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Rasmane Semde, General Director, Direction de la Pharmacie et du Medicament, Burkina Faso
Yakubu Nyam Beno, Chair, African Vaccine Regulatory Forum (AVAREF), Nigeria
Sandor Kerpel-Fronius, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Hungary
Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Ahmed Bellah, World Health Organization (WHO), Switzerland
Alexander Dodoo, Director, The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Ghana

12:30  LUNCH  SALON FLAMBOYANT

14:00  SESSION 10 – STAKEHOLDERS WORKSHOPS

These sessions are set-up as a panel discussions with regulators or industry representatives only respectively. Main discussion points, comments and recommendations from these sessions as recorded by a rapporteur will be shared during next plenary session. Regulators’ and industry’s views of needs and opportunities for improvement related to the discussion points will be brought into perspective with each other during the sessions.

**Workshop G | Room C01**

**Regulators’ closed panel discussion**

Chair: Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Moderator: Samvel Azatyan, Group Lead, Capacity Building and Harmonization Support, World Health Organization (WHO), Switzerland
Rapporteur: Amadou Moctar Dieye, Director, Direction de la Pharmacie et du Medicament, Senegal
Discussants: Representatives of Regulatory Authorities

**Workshop H | Room BC12**

**Industry and Stakeholders’ closed panel discussion**

Chair: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Moderator: Oumkaltoum Lahlou, Head of Regulatory Affairs North & West Africa, Merck, Tunisia
Co-Moderator: Mercè Caturla, Janssen Pharmaceutical companies of Johnson & Johnson, Belgium
Rapporteur: William Mwatu, Chairman, Kenya Association of the Pharmaceutical Industry (KAPI), Kenya
Discussants: Representatives of Industry

15:30  COFFEE BREAK & NETWORKING IN THE EXHIBITION HALL  ROOM B01

16:00  SESSION 11 – PLENARY | ROOM BC12

RECAP FROM PARALLEL WORKSHOPS

Chairs: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA, and Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso
Amadou Moctar Dieye, Director, Direction de la Pharmacie et du Medicament, Senegal
William Mwatu, Chairman, Kenya Association of the Pharmaceutical Industry (KAPI), Kenya
Samvel Azatyan, Group Lead, Capacity Building and Harmonization Support, World Health Organization (WHO), Switzerland
Oumkaltoum Lahlou, Head of Regulatory Affairs North & West Africa, Merck, Tunisia
Mercè Caturla, Janssen Pharmaceutical companies of Johnson & Johnson, Belgium

16:45  SESSION 12 PART 1 – PLENARY | ROOM BC12

CHALLENGES / BARRIERS TO ACCESS MEDICINES

The millennium development goals and the drive for universal health coverage require that patients have access to quality-assured medical products. Partners worldwide are working together to ensure sustainable and affordable access to treatment. Different measures are being worked out, from strengthening existing and building new research capacity, opening the door to generic low-cost production to supporting the delivery of medicines. Challenges and barriers will be discussed during this session, followed by the recommendations and closing remarks of the conference.

Chair: Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Greg Perry, Executive Director, Medicines Patent Pool (MPP), Switzerland
Nathalie Strub Wourgaft, Medical Director, Drugs for Neglected Diseases Initiative (DNDi), Switzerland

17:45  SESSION 12 PART 2 – PLENARY | ROOM BC12

RECOMMENDATIONS FROM THE CONFERENCE

Vincent I. Ahonkhai, Senior Advisor, Global Health, Bill & Melinda Gates Foundation, USA
Corneille Traore, Director, West African Economic and Monetary Union (UEMOA), Burkina Faso

18:30  END OF THE CONFERENCE
CONTINUING EDUCATION

DIA meetings and training courses are generally approved by the Commission for Professional Development (CPD) of the Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society of Pharmaceutical Medicine (SGPM) and will be honoured with credits for pharmaceutical medicine. This event has been accredited with 12 credits. All participants are eligible for these credits.

EVALUATION

We value your feedback on the content and organisation of this conference. The electronic survey will be sent to you after the conference and can also be accessed through the following link: https://www.surveymonkey.com/s/15105

PRESENTATION ACCESS INFORMATION

As a benefit of registration, presentations are available on the DIA website. Please log in to MyDIA and choose "My Presentation Downloads", where you will be able to download all presentations that have been submitted by speakers.

Note: You will need to enter your DIA User ID and password to verify your status. If you have forgotten your DIA User ID and password, use the Login Reminder.

After logging in to My DIA, you will see presentation PDFs from all the DIA offerings you have attended in the past 6 months. Simply choose the presentation you would like to view or download.

Please note that if a presentation is not available on the website, it is because:
• The presenter has not supplied us with a presentation file
• There was no slide presentation planned by the speaker
• The speaker did not agree to share it with other participants
• You have not yet paid the registration fee

CERTIFICATE OF ATTENDANCE

A Certificate of Attendance will be e-mailed to all attendees after they have filled in the evaluation. Please note certification requires full attendance to the event. For more information please contact DIA EMEA Contact Center on diaeurope@diaeurope.org or call +41 61 225 51 51.

EXHIBITION

On behalf of DIA and IFPMA welcome and thank you to Conference exhibitor Pharmaly and sponsors Bill & Melinda Gates Foundation and World Bank.
<table>
<thead>
<tr>
<th>Last name</th>
<th>First name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahonkhai</td>
<td>Vincent</td>
<td>Bill &amp; Melinda Gates Foundation, USA</td>
</tr>
<tr>
<td>Azatyan</td>
<td>Samvel</td>
<td>World Health Organisation, Switzerland</td>
</tr>
<tr>
<td>Beliah</td>
<td>Ahmed</td>
<td>World Health Organisation, Switzerland</td>
</tr>
<tr>
<td>Beno</td>
<td>Yakubu</td>
<td>African Vaccine Regulatory Forum (AVAREF), Nigeria</td>
</tr>
<tr>
<td>Benoist</td>
<td>Fabienne</td>
<td>Novartis Pharma, Switzerland</td>
</tr>
<tr>
<td>Cantú Gonzalez</td>
<td>Mauricio</td>
<td>Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris), Mexico</td>
</tr>
<tr>
<td>Caturla</td>
<td>Merce</td>
<td>Janssen Pharmaceutical Companies, Belgium</td>
</tr>
<tr>
<td>Darko</td>
<td>Delese Mimi</td>
<td>Food and Drug Authority, Ghana</td>
</tr>
<tr>
<td>Dearden</td>
<td>Paul</td>
<td>Abbvie, UK</td>
</tr>
<tr>
<td>Dieye</td>
<td>Amadou Moctar</td>
<td>Ministry of Health, Senegal</td>
</tr>
<tr>
<td>Dodoo</td>
<td>Alexander</td>
<td>World Health Organisation Africa, Ghana</td>
</tr>
<tr>
<td>Dörr</td>
<td>Petra</td>
<td>Swissmedic, Switzerland</td>
</tr>
<tr>
<td>Engleman</td>
<td>Carl</td>
<td>Pfizer, United Arab Emirates</td>
</tr>
<tr>
<td>Gwaza</td>
<td>Luther</td>
<td>Medicines Control Authority, Zimbabwe</td>
</tr>
<tr>
<td>Jaiyeola</td>
<td>Osarein</td>
<td>Fensyl MHP Consulting Ltd, Ghana</td>
</tr>
<tr>
<td>Kerpel-Fronius</td>
<td>Sandor</td>
<td>Semmelweis University, Hungary</td>
</tr>
<tr>
<td>Kimou</td>
<td>Stephanie</td>
<td>Ministry of Health, Ivory Coast</td>
</tr>
<tr>
<td>Lahlou</td>
<td>Oumkaltoum</td>
<td>Merck North West Africa, Morocco</td>
</tr>
<tr>
<td>Lyngvig</td>
<td>Jytte</td>
<td>DIA Europe, Middle East and Africa, Switzerland</td>
</tr>
<tr>
<td>Mwatu</td>
<td>William</td>
<td>Kenya Association of the Pharmaceutical Industry, Kenya</td>
</tr>
<tr>
<td>Mwesigye</td>
<td>John Patrick</td>
<td>East African Community – Medicines Regulation and Harmonisation, Tanzania</td>
</tr>
<tr>
<td>Narsai</td>
<td>Kirti</td>
<td>Johnson &amp; Johnson, South Africa</td>
</tr>
<tr>
<td>Ndomondo-Sigonda</td>
<td>Margaret</td>
<td>The New Partnership For Africa’s Development (NEPAD), South Africa</td>
</tr>
<tr>
<td>Nyirenda</td>
<td>Thomas</td>
<td>European Development Partnership on Clinical Trials, South Africa</td>
</tr>
<tr>
<td>Omobo</td>
<td>Oluwaseun Ayobami</td>
<td>National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria</td>
</tr>
<tr>
<td>Ossei-Agyeman-Yeboah</td>
<td>Sybil</td>
<td>West African Health Organization (WAHO), Burkina Faso</td>
</tr>
<tr>
<td>Perry</td>
<td>Greg</td>
<td>Medicines Patent Pool (MPP), Switzerland</td>
</tr>
<tr>
<td>Sailléz</td>
<td>Christophe</td>
<td>GSK, France</td>
</tr>
<tr>
<td>Seiter</td>
<td>Andreas</td>
<td>World Bank, USA</td>
</tr>
<tr>
<td>Semde</td>
<td>Rasmame</td>
<td>General Director of Pharmacy, Medicines and Laboratories (DGPML), Burkina Faso</td>
</tr>
<tr>
<td>Sillo</td>
<td>Hiti</td>
<td>Food and Drug Authority, Tanzania</td>
</tr>
<tr>
<td>Simonian</td>
<td>Elliot</td>
<td>GSK, UK</td>
</tr>
<tr>
<td>Smid</td>
<td>Milan</td>
<td>World Health Organisation, Switzerland</td>
</tr>
<tr>
<td>Strub-Wourgaft</td>
<td>Nathalie</td>
<td>Drugs for Neglected Diseases initiative (DNDi), Switzerland</td>
</tr>
<tr>
<td>Traore</td>
<td>Corneille</td>
<td>West African Monetary and Economic Union (UEMOA), Burkina Faso</td>
</tr>
<tr>
<td>Wasike</td>
<td>Jacinta</td>
<td>Pharmacy and Poisons Board, Kenya</td>
</tr>
<tr>
<td>Yissibi Pola</td>
<td>Emilienne</td>
<td>Organization for the coordination of the fight against endemic diseases in Central Africa (OCEAC), Cameroon</td>
</tr>
<tr>
<td>Taute</td>
<td>Estelle</td>
<td>Medicines Regulatory Authority, South Africa</td>
</tr>
</tbody>
</table>
CONFERENCE CO-CHAIRS

Vincent Ahonkhai MD, FAAP
Senior Advisor Global Health at the Bill & Melinda Gates Foundation

Previous position/Career highlights:
Until recently, he was Deputy Director Global Health and Head of Regulatory Affairs at the foundation, a functional team that he built from 2008. In that role he was responsible for the foundation’s cross-cutting Regulatory Affairs strategy for global health products, i.e. therapeutics, vaccines, diagnostics and vector control products. The strategy focuses on the optimizing of global, regional and national regulatory pathways for maximum impact in the development, licensure and country registration of foundation priority products in low- and middle-income countries. Dr. Ahonkhai has over two decades of experience in academic and pharmaceutical R&D and Medical Affairs in multiple therapeutic and preventive product categories. He has worked in multi-national pharmaceutical firms including most recently GlaxoSmithKline where served in positions of increasing responsibility and leadership for 13 years. Before joining the foundation, he was Vice President Regulatory Affairs, GSK Biologicals. Dr. Ahonkhai is a board-certified paediatrician with subspecialty in Infectious diseases, and a Fellow, Infectious Disease Society of America. He has presented scientific papers in several infectious disease fora and published extensively in peer-reviewed journals. Dr. Ahonkhai obtained his medical degree from the University of Lagos, Nigeria, his paediatric and subspecialty training from the State University of New York, Downstate.

Corneille TRAORE, MD, PhD, MSc
Directeur de la Santé, de la Protection Sociale et de la Mutualité à la Commission de l’Union Economique et Monétaire Ouest Africaine (UEMOA).

Current position:
A ce titre, coordonnateur du Secrétariat de la Cellule d’Harmonisation de la Réglementation et la Coopération pharmaceutique (CHRCP) de l’UEMOA.

Previous position/Career highlights:
1987-1988 : Médecin clinicien à l’Hôpital National de Ouagadougou, Burkina Faso
1988-1990 : Médecin-chef de district sanitaire de Gourcy, Burkina Faso
1995-1997 : Chef de service Coopération à la Direction des Etudes et de la Planification du Ministère de la Santé (DEP), Burkina Faso
2003-2004 : Chargé de suivi évaluation au Secrétariat Technique de suivi du Plan National de Développement Sanitaire (ST/PNDS)
2004-2005 : Coordonnateur de la Cellule d’Appui à la Décentralisation du Système Sanitaire (CADSS)
2006-2007 : Chargé de programme Santé à la Commission de l’Union Economique et Monétaire Ouest Africaine (UEMOA), Ouagadougou, Burkina Faso
2007 à nos jours : Directeur de la Santé, de la Protection Sociale et de la Mutualité à la Commission de l’UEMOA, Ouagadougou, Burkina Faso.

SPEAKERS

Samvel AZATYAN, M.D., Ph.D.
Group Lead, Capacity Building and Harmonization Support, Regulatory Systems Strengthening (RSS), Department of Essential Medicines and Health Products (EMP), World Health Organization; Programme Manager, Regulatory Support Programme, WHO.

Current position:
Currently Dr Azatyan is a Group Lead in the Regulatory Systems Strengthening team which is part of the Department of Essential Medicines and Health Products.

Previous position/Career highlights:
Dr Samvel Azatyan is a clinical pharmacologist, with a Ph.D. degree in clinical pharmacology and medicines regulation. From 1992 Dr Azatyan has served as a deputy director of the National Medicines Regulatory Authority of Armenia. In 1999 Dr Azatyan began his work at the World Health Organization, initially at the WHO Regional Office for Europe, in Copenhagen, Denmark, and in 2003 joined the WHO Headquarters in Geneva, Switzerland.
**Paul H DEARDEN, BSc (Hons)**
Director, Regulatory Policy & Intelligence, AbbVie, UK

**Current position:**
Director, Regulatory Policy & Intelligence at AbbVie with a particular focus on Africa, Middle East and Eastern Europe.

**Previous position/Career highlights:**
Responsible for Regulatory Policy for all emerging markets at GSK.

---

**Alexander DODOO, B.Pharm, MSc, PhD, FPSGH, FPCPharm**
Associate Professor, Centre for Tropical Clinical Pharmacology, School of Medicine and Dentistry; Director, WHO Collaborating Centre for Advocacy and Training, University of Ghana

**Current position:**
He serves on several local and international advisory, training and safety committees, including Member, WHO Advisory Committee on the Safety of Medicinal Products, Member, Access and Delivery Advisory Committee of the Medicines for Malaria Venture and Chairman of the Global Vaccine Safety Initiative.

**Previous position / Career highlight:**
He was for two terms (4 years), the President of the Pharmaceutical Society of Ghana and served as President of the Pharmacy Information Section of the International Pharmaceutical Federation. He is a longstanding member of numerous professional pharmaceutical associations and is the recipient of the Senior Pharmacovigilance Fellowship Award from the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden. Prof Dodoo was a member of the Drug Resistance Working Group of the Centre for Global Development which produced the influential and highly cited report “The Race Against Drug Resistance” in 2010. He is the author/co-author of various manuscripts and full papers in peer-reviewed journals and has one book published titled: Healthy Secrets – a layperson’s guide to health issues.

---

**Amadou Moctar DIEYE, PhD**
Pharmacien lieutenant-colonel, Professeur Titulaire des Universités en Pharmacologie,

**Previous position / Career highlight:**
Professeur titulaire des Universités depuis juillet 2008 à l’UCAD
Chef du département des sciences biologiques et pharmaceutiques appliquées de la section Pharmacie de la Faculté de Médecine de 2005 à 2007
Membre du comité d’éthique du Sénégal de 2004 à 2008
Pharmacie responsable du bureau de la Pharmacopée « Moderne » à la Direction de la Pharmacie et des Laboratoires du Sénégal de 2002 à 2006
Pharmacie responsable de la Pharmacovigilance au Centre Anti-Poison du Sénégal de septembre 2009 à octobre 2012
Coordonnateur du Master de Pharmacie Hospitalière et des Collectivités depuis 2008-2009 au niveau de l’UCAD
Ancien interne des hôpitaux de Dakar en Pharmacie de 1989 à 1991
Lieutenant-colonel dans l’Armée Sénégalaise depuis le 1er janvier 2011
Directeur de la Pharmacie et du Médicament depuis septembre 2013
Petra DÖRR, PhD
Head of Communication and Networking and Deputy Director at Swissmedic, Swiss Agency for Therapeutic Products, Switzerland

Current position:
Petra oversees the international activities of Swissmedic with other agencies and international organisations, amongst other responsibilities in external relations as a part of her role since 2014. She is a member of the ICH Steering Committee for Swissmedic and of the Scientific Advisory Council of the Centre for Innovation in Regulatory Science and currently serves as the chair of the International Pharmaceutical Regulators Forum (IPRF).

Previous position / Career highlight:
Petra Dörr received her approbation as a pharmacist in 1990 and was awarded her PhD at the Institute of Pharmaceutical Chemistry, Faculty of Pharmacy at the University of Heidelberg in 1995. She has ten years of experience in international regulatory affairs. Before joining Swissmedic, she held the position of Vice President Regulatory Affairs in Europe, Africa and Asia at Valeant Pharmaceuticals, Inc. In October 2004, she started at Swissmedic as the Head of International Affairs. She has been Head of Management Services & Networking and Member of the Management Board at Swissmedic, Swiss Agency for Therapeutic Products, since July 2007.

Carl ENGLEMAN
Country Manager and Business Unit Lead for the Global Established Pharma business in Nigeria & East Africa Region (NEAR), Pfizer, UK

Current position:
Since late 2013 Carl has been the Country Manager for Pfizer NEAR, responsible for building a successful and sustainable business model for these dynamic markets. Pfizer NEAR is responsible for the direct employment of over 100 local staff, working to bring Pfizer medicines to healthcare practitioners and patients. The NEAR region includes two major offices, in Nairobi and Lagos, and covers 9 countries.

Previous position / Career highlight:
Carl Engleman has 17 years of pharmaceutical industry experience, 15 of which have been with Pfizer. He began his career in Pfizer UK working in Sales and Marketing before moving into a regional team and helping to establish a regional marketing model for Europe. In 2008 Carl moved to Dubai as part of a small team tasked with developing a regional hub model for Africa and the Middle East, expanding his role further into the areas of Supply Chain optimisation, Channel Management and Commercial Compliance.

Luther GWAZA, B.Pharm. (Hons), MPhil
Medicines Control Authority of Zimbabwe, Zimbabwe

Current Position:
Consultant (Chief) Regulatory Officer

Previous position / Career highlights:
Luther is a pharmacist with experience in medicines regulation spanning clinical trials oversight, pharmacovigilance, and currently pre-marketing assessment and registration of medicines. Luther has been involved in various assignments on strengthening medicines regulatory systems in the Southern African region and Central Asia. He is currently a professional PhD student with the Utrecht – WHO Collaborating Centre in Pharmaceutical Policy and Regulation in the Netherlands.
Osaretin JAIYEOLA, B.Pharm., MSc  
Managing Director & Principal Partner, Fensyl MHP Consulting Limited, Nigeria

Current position:
African based Regulatory-consulting Company providing Intelligent Regulatory solutions to Africa

Previous position / Career highlight:
Osaretin has been in pharmaceutical industry from 1991 with a series of senior management roles, with primary focus on the Sub-Saharan Africa (SSA) region.
From 2000, Head of Regulatory Affairs for Anglophone Africa at GSK Consumer Nigeria Plc and later Director of Regulatory Affairs for Anglophone West Africa.
In 2009, Director of Regulatory Affairs for Sub-Saharan Africa and later in 2010 was also responsible for the GSK Regulatory Team in Morocco, Tunisia and Libya.
From 2014, Director of Regulatory Affairs at GSK Pharmaceuticals-Africa, Cluster Lead for West Africa and responsible for coordinating New Product Introduction activities pan-Africa. She led a diverse regulatory team with expertise in a wide range of therapeutic areas and processes - from pharmaceuticals and biotechnology to clinical trials, submissions and follow-up.
While at GSK Consumer Nigeria Plc, Osaretin served on the company’s Board for a period of 9 years, as Executive Director then as Non-Executive Director.

Sandor KERPEL-FRONIUS, PhD
Professor of Clinical Pharmacology, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary

Previous position / Career highlight:
Medical diploma and board certificates in Clinical Laboratory Sciences and Clinical Pharmacology. Research in neurobiology in Hungary and as research fellow in Sweden and in the US. From 1975 clinical research at the Hungarian National Institute of Oncology, later in the international pharmaceutical industry.
Committee memberships: IFAPP, EACPT, IMI-PharmaTrain, OECD.

Oumkaltoum LAHLOU, Pharmacist
Head of Regulatory Affairs, North and West Africa, Merck

Previous position / Career highlight:
October 2013 – November 2013: Head of Regulatory Affairs, North and West Africa, Alcon
January 2006 – October 2013: Regulatory Affairs Manager, Bayer

Jytte LYNGVIG, PhD
Senior Vice President and Managing Director for DIA Europe, Middle East & Africa

Previous position / Career highlight:
Between 2000 – 2013, Jytte Lyngvig was the Executive Director of the Danish Medicines Agency and a member of the European Medicines Agencies Management Board. She served for 5 years as a vice chair of this Board and for 6 years as the char of the Management Group of the Heads of Medicines Agencies.
She is educated as chemical engineer and has a Ph.D. in Mathematical Statistics and Operations Research, plus a business certificate in French.
John Patrick MWESIGYE, MSc
Senior Health Officer. East African Community (EAC) Secretariat

Current position:
Currently a Senior Health Officer at the East African Community Secretariat, responsible for Medicines Regulation Harmonization Project, since 1st July 2013.

Previous position / Career highlight:
From September 2009 to June 2013, Head of Pharmaceutical Policy and Medicines Regulatory Body in Republic of Rwanda and Chair of the National Pharmaceutical Establishments Committee. A member of the National Technical Requirements and Specification Committee in Rwanda, and coordinator for the health commodities committee in Rwanda and including Coordinated Procurement and Distribution System activities. An Active Member of the EAC Technical team on matters related to food and medicines safety committee, including the various TWGs on MRH from 2009. In addition an inspector of pharmaceutical establishments in the Republic of Rwanda 2005 – 2009.

He received his B. Pharm from the Tamil Nadu Dr. MGR Medical University Chennai – India April 2003 and his Master’s degree in Clinical Pharmacy from the University of Nairobi, Kenya Dec 2008. In addition, he has undergone a number of other professional supportive and professional carrier development training programmes in Health and related sectors.

Kirti NARSAI, MSc (Pharm), MBA
Director, Government Affairs & Policy, Johnson & Johnson, South Africa

Current position:
Responsible for proactively assessing, influencing and shaping the rapidly evolving Health Policy environment in South Africa in close collaboration and partnering with internal and external stakeholders across all three business sectors.

Previous position / Career highlight:
Head of Scientific and Regulatory Affairs at the Pharmaceutical Industry Association of South Africa (PIASA). The role focused on strategic scientific, health and pharmaceutical policy issues affecting pharmaceutical companies operating in South Africa and also other African countries across 4 regional economic communities.

Kirti began her career in the pharmaceutical industry with Janssen in 1997 in the areas of Medical Affairs and Pharmacovigilance. Subsequent to this, she also held several positions of increasing responsibility in the area of Medical Affairs at AstraZeneca Pharmaceuticals. She was also employed as a Programme Manager at a leading health insurance company, PruHealth (a division of Discovery Health).

Margareth NDOMONDO-SIGONDA, MSc, MBA
New Partnership for Africa’s Development (NEPAD) Agency, South Africa

Current position:
Joined the African Union - NEPAD Agency as the Pharmaceutical Coordinator (2010-To Date) responsible for coordination of the African Medicines Regulatory Harmonization initiative.

Previous position / Career highlight:
Served as Chief Pharmacist (1998), Registrar of Pharmacy Board (1998-2003) and Director General of the Tanzania Food and Drugs Authority (2003-2010). Holds MSc degree in pharmaceutical services management, University of Bradford United Kingdom; MBA the Eastern and Southern Africa Management Institute-Tanzania/ Maastricht School of Management-Netherlands; and bachelor’s degree in pharmacy from the University of Dar es Salaam, Tanzania.
Thomas NYIRENDA, MD, MSc
South-South Networking and Capacity Development Manager, EDCTP, South Africa

Previous position / Career highlights:
TN is a public health physician with 20 years' experience in disease control programs, operational field research and clinical trials in sub-Saharan Africa. He previously worked in Ministry of Health in Malawi and the World Health Organisation (WHO) in Geneva and Malawi. In the last 10 years he has worked as clinical research networking and capacity development manager for the European and Developing Countries Clinical Trials Partnership (EDCTP) where the current portfolio contains 246 research projects in sub-Saharan countries that include 100 multi-site clinical trials in 30 African countries in partnership with institutions from 16 European countries, numerous networking projects involving 1271 African and European researchers, 514 personnel in training, training of national regulatory authorities, strengthening of 60 ethics committees and maintenance of the first Pan African Clinical Trials Registry (PACTR) at the Cochrane Centre in Cape Town.

Paul B. ORHI, JD, MD, PhD, OON - replaced by Oluwaseun Ayobami Omobo
Director General, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria.

Current position:
Charged with the responsibility of regulating and controlling the importation exportation, manufacture, advertisement, sale and use of regulated products in Nigeria; he has put in place several regulatory reforms. Since assuming office, he has strengthened the Agency’s regulatory capacity and fostered unprecedented National/Regional/International cooperation and collaboration. This includes but is not limited to the support of local pharmaceutical manufacturing by the World Health Organization (WHO) Prequalification Programme in Nigeria; a quality assurance initiative which has since produced the first four companies in West Africa to be certified by WHO to have attained best international standards in Pharmaceutical Manufacturing.

Previous position / Career highlights:
A consummate professional, his training as a Medical Doctor, a Chrono-Neuropsychopharmacologist, a Biomedical Scientist and an Attorney has stood him in good stead in the discharge of his duties.

Furthermore, he has keyed into global initiatives that enhance regulation and entrenched the agency’s position as one of the top 20 medicines regulatory agencies in the world. He has received several prestigious awards both nationally and internationally. In recognition of his immense contributions to national development, he was awarded the prestigious Nigerian National Honour of the Officer of the Niger (OON).

Sybil Nana Ama OSSEI-AGYEMAN-YEBOAH, B.Pharm., MSc
Professional Officer Essential Medicines and Vaccines, West African Health Organization (WAHO)

Current position:
My current job deals greatly in the development of policies, legislations, regulation and guidelines, capacity building to create local experts to strengthen the human resource job force in the Economic Community of West African States (ECOWAS). Collaborate, coordinate and cooperate with various partners and stakeholders both regionally and internationally to put technical, financial and know-how together to enhance the public health interventions to improve on the health of the population in the region.

Previous position / Career highlights:
Administrative and Management Consultant, License Member of both Chartered Institute of Administration and Management Consultants-Ghana and International Professional Management Association -UK, from 2007. Lecturer at Kumasi Polytechnic, from 1990- July 2003, Head of Manufacturing unit at Komfo Anokye Teaching Hospital at from 2003 July -January 2010. Vice-President of Ladies Pharmacists Association of Ghana (LAPAG) from 2003-2005 and President from 2005-2010. Governing Board Member, Constitutional Committee Member, Public Health Committee Member and Director of Governance and Non-Governance Directorate, Pharmaceutical Society of Ghana (PSGH) 2005-2010, Ghana Representative for the Africa Pharmaceutical Forum (APF) issues in International Pharmaceutical Federation (FIP). Currently, the Professional Officer in charge of Essential Medicines and Vaccines in West African Health Organization (WAHO). AU/NEPAD/AMRH Advisory Committee Member, Observer Status of the United State Pharmacopoeial (USP/PQM) Convention and a member of the United State Pharmacopoeial (USP), Centre for Pharmaceutical Advancement and Training (CePAT) Advisory Group
Greg Perry

Executive Director, Medicines Patent Pool, Switzerland

Current position:

Greg Perry joined the Medicines Patent Pool (MPP) as Executive Director in January 2013.

Previous position / Career highlights:

Prior to his role at MPP, Perry served as Founding Director and later Director General of the European Generic Medicines Association.

Emilienne Pola Yissibi, Pharmacien, Santé Publique

Public Health Pharmacist, Organization for the Coordination of the Fight Against Endemic Diseases in Central Africa (OCEAC), Cameroon

Current Position:

Consultant; General Secretary of the National Council of the Order of the Pharmacists, Cameroon.

Previous position/Career highlights:

Coordinator of the program “Harmonization of the National Pharmaceutical Policies in Central Africa” / OCEAC.

Expert in policies and pharmaceutical regulations in Yaoundé (Cameroon), Direction of the Pharmacy and Medicine: Chief of service of homologation and pharmacovigilance.

Temporary replacement Teacher and internship supervisor at the University Yaoundé 1, Faculty of Medicine and Biomedical Sciences, Department of galenic Pharmacy and pharmaceutical legislation.

Prize of the French-speaking pharmacy (Académie française de la Pharmacie, Prize list 2012).

Andreas Seiter, MD

Senior Health Specialist – Pharmaceuticals, The World Bank

Current position:

Andreas Seiter is a Senior Health Specialist and expert for pharmaceutical policy and management at the World Bank’s Health, Nutrition and Population Anchor. He joined the Bank in January 2004 and is responsible for analytical and advisory work in all areas of pharmaceutical policy, such as regulation, governance, quality assurance, financing, pharmacy benefit management, supply chain and rational use. He has been working with Bank teams, policy makers and experts on the client side in more than 25 countries in Africa, Eastern Europe, the Middle East, Latin America and South Asia. In addition to pharmaceutical policy, he is also working on related areas such as medical devices management and use of new technologies to improve health system performance.

Previous position / Career highlights:

Dr. Seiter, a German national, is a physician by training and practiced medicine before joining a multinational pharmaceutical company in 1984. He held various positions in Medical Operations, Product Management, Communications and Stakeholder Relations in the industry prior to joining the Bank.

Rasmané Semde, Professor

General Director of Pharmacy, Medicines and Laboratories (DGPML), Burkina Faso

Previous position / Career highlights:

Professor of Pharmacy and Biopharmacy, University of Ouagadougou, Burkina Faso
Hiiti SILLO, B. Pharm., MSc
Director General, Tanzania Food and Drugs Authority (TFDA), Tanzania

Current position:
Mr. Hiiti Sillo is the Director General of the Tanzania Food and Drugs Authority (TFDA) from June 2011 after acting in the same capacity since May 2010. Prior to his current position, he served the TFDA on several technical and managerial positions including being the Director of Medicines and Cosmetics between 2008 and 2011.

Previous position / Career highlights:
Mr. Sillo is a career Medicines Regulator and a registered Pharmacist with regional and international experience in medicines regulation and quality assurance of pharmaceuticals. He served WHO Prequalification of Medicines Programme as a Quality Assessor from 2003 to 2010 that included working as a Technical Officer at WHO HQ in Geneva on a rotational position in 2007. He serves in various technical and advisory Boards and Committees at national, regional and international level including being the current member of the WHO Strategic and Technical Advisory Group (STAG) on Antimicrobial Resistance.

Elliot SIMONIAN, BSc
Head of Regulatory Affairs – Africa, GlaxoSmithKline, UK

Current position:
Area Regulatory Head for Africa for GlaxoSmithKline's Pharmaceutical division, leading the local and above country area regulatory teams.

Previous position / Career highlights:
Regulatory Director within GlaxoSmithKline’s Emerging Market and Asia Pacific Region.
Over 15 years experience in the Pharmaceutical industry providing regulatory leadership to emerging markets, to business development teams, to both new and established products and within CMC regulatory affairs

Milan SMID, MD, PhD
Group Lead, Technical Assistance and Laboratory Services, Prequalification Team, Regulation of Health Products, World Health Organization

Previous position / Career highlights:
10 years in the pre-clinical and clinical development of medicines,
5 years of lecturing basic and clinical pharmacology at Charles University in Prague,
13 years as the director of the State Regulatory Authority in the Czech Republic, playing an active role in the transformation of the national regulatory system to cope with EU standards and serving in several EU regulatory and scientific bodies (EMA CHMP and Management Board, Pharmaceutical Committee of European Commission and Heads of EU Medicines Agencies).
Since 2007 he is a technical officer within WHO, currently leading the Technical Assistance and Laboratory Services group in the Prequalification Team, with special responsibility for capacity building, trainings, co-operation with National Regulatory Authorities and support to manufacturers.

Jacinta WASIKE, PhD
Deputy Chief Pharmacist Ministry of Health, Kenya
Director Inspection, Surveillance and Enforcement Pharmacy and Poisons Board, Nairobi, Kenya.

Previous position / Career highlights:
Jacinta Wasike has worked in Regulatory Affairs for Pharmaceuticals for the past 15 years.
INVITED REGULATORY AUTHORITIES

<table>
<thead>
<tr>
<th>Last</th>
<th>First</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amedzro</td>
<td>Thomas</td>
<td>Food and Drug Authority, Ghana</td>
</tr>
<tr>
<td>Atai</td>
<td>Messan Adodo</td>
<td>Direction des Pharmacies, Ministry of Health, Togo</td>
</tr>
<tr>
<td>Bamenyekanye</td>
<td>Emmanuel</td>
<td>Direction de la Pharmacie et du Medicament et des Laboratoires, Ministry of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Public Health, Burundi</td>
</tr>
<tr>
<td>Coulibaly</td>
<td>Yaya</td>
<td>Direction de la Pharmacie et du Medicament, Ministry of Health, Mali</td>
</tr>
<tr>
<td>Da Costa Gomes</td>
<td>Zeferina</td>
<td>Direction de la Pharmacie et du Medicament, Guinea Bissau</td>
</tr>
<tr>
<td>Elkaranfily</td>
<td>Hassan Ahmed Hassan</td>
<td>Egyptian Drug Authority, Egypt</td>
</tr>
<tr>
<td>Gisagara</td>
<td>Alex</td>
<td>Ministry of Health, Rwanda</td>
</tr>
<tr>
<td>Jah</td>
<td>Fatoumata</td>
<td>Medicines Control Agency, Gambia</td>
</tr>
<tr>
<td>Johnson</td>
<td>Wiltshire</td>
<td>Pharmacy Board, Sierra Leone</td>
</tr>
<tr>
<td>Angole</td>
<td>Apollo</td>
<td>National Drug Authority, Uganda</td>
</tr>
<tr>
<td>Hounkpevi</td>
<td>Benoit</td>
<td>Direction de la Pharmacie et du Medicament, Ministry of Public Health, Benin</td>
</tr>
<tr>
<td>Messan</td>
<td>Halimatou Allasane</td>
<td>Direction de la Pharmacie et du Medicament, Ministry of Public Health, Niger</td>
</tr>
<tr>
<td>Ngeleka Mutolo</td>
<td>Daniel</td>
<td>Direction de la Pharmacie et du Medicament, Ministry of Public Health, Congo</td>
</tr>
<tr>
<td>Ogbeide</td>
<td>Edosa</td>
<td>National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria</td>
</tr>
<tr>
<td>Semde</td>
<td>Rasmane</td>
<td>Direction Générale de la Pharmacie, du Médicament et des Laboratoires, Burkina Faso</td>
</tr>
<tr>
<td>Tarpeh</td>
<td>Hasipha C.</td>
<td>Medicines &amp; Health Products Regulatory Authority (LMHRA), Liberia</td>
</tr>
<tr>
<td>Tavares</td>
<td>Eduardo</td>
<td>Agência de Regulação e Supervisão dos Produtos Farmacêuticos e Alimentares, Cape Verde</td>
</tr>
</tbody>
</table>

ABOUT DIA

Health issues know no borders. Fortunately, neither do innovative ideas, novel treatments and effective drug development designed to address these concerns.

DIA is the only organization that enables everyone involved in health product development to share information on a global scale. Our goal is simple: to improve health and well-being by transferring knowledge from those who have it to those who need it.

It’s All about Connections: Since 1964, DIA has been connecting people and ideas to address the most pressing global health issues.

DIA members—regulators, researchers, industry professionals, advocates and patients—join for a variety of reasons but share the common goal of improving human health and well-being worldwide.

ABOUT IFPMA

Founded in 1968, the IFPMA is a global, non-profit, nongovernmental organisation. With members across the globe and a secretariat based in Geneva, Switzerland, the IFPMA represents the research-based pharmaceutical industry, including the biotechnology and vaccine sectors.

Our members comprise leading international companies as well as national and regional industry pharmaceutical associations in both developing and developed countries. Our primary role is to improve global health by representing our members in dialogue with intergovernmental bodies, nongovernmental organisations, Geneva-based missions of national governments, civil society organisations and others.

The IFPMA has several expert committees and working groups which leverage industry expertise to develop effective approaches to health issues.

For more information, visit www.ifpma.org or call IFPMA +41 22 338 32 00.